ECSP088329A - Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8 - Google Patents

Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8

Info

Publication number
ECSP088329A
ECSP088329A EC2008008329A ECSP088329A ECSP088329A EC SP088329 A ECSP088329 A EC SP088329A EC 2008008329 A EC2008008329 A EC 2008008329A EC SP088329 A ECSP088329 A EC SP088329A EC SP088329 A ECSP088329 A EC SP088329A
Authority
EC
Ecuador
Prior art keywords
diazaespiroalcanos
ccr8
treatment
new
diseases mediated
Prior art date
Application number
EC2008008329A
Other languages
English (en)
Inventor
Stephen Connolly
Lena Boerjesson
Henrik Johansson
Anna Kristoffersson
Tero Linnanen
Igor Shamovsky
Marco Skrinjar
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP088329A publication Critical patent/ECSP088329A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención provee compuestos de la fórmula general (I), en donde A, B, p, w, x, y y z tienen las definiciones indicadas en la descripción, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia.
EC2008008329A 2005-09-06 2008-03-28 Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8 ECSP088329A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0501967 2005-09-06

Publications (1)

Publication Number Publication Date
ECSP088329A true ECSP088329A (es) 2008-04-28

Family

ID=37836107

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008329A ECSP088329A (es) 2005-09-06 2008-03-28 Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8

Country Status (17)

Country Link
US (1) US20090156575A1 (es)
EP (1) EP1926730A4 (es)
JP (1) JP2009507070A (es)
KR (1) KR20080043396A (es)
CN (1) CN101305005A (es)
AR (1) AR055630A1 (es)
AU (1) AU2006287976A1 (es)
BR (1) BRPI0615634A2 (es)
CA (1) CA2621187A1 (es)
EC (1) ECSP088329A (es)
IL (1) IL189528A0 (es)
NO (1) NO20081729L (es)
RU (1) RU2008110915A (es)
TW (1) TW200800999A (es)
UY (1) UY29781A1 (es)
WO (1) WO2007030061A1 (es)
ZA (1) ZA200801511B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378525B2 (en) 2002-12-23 2008-05-27 Millennium Pharmaceuticals, Inc. CCR8 inhibitors
TW200510311A (en) 2002-12-23 2005-03-16 Millennium Pharm Inc CCr8 inhibitors
US7491827B2 (en) 2002-12-23 2009-02-17 Millennium Pharmaceuticals, Inc. Aryl sulfonamides useful as inhibitors of chemokine receptor activity
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
DK2379525T3 (en) 2008-12-19 2015-10-19 Boehringer Ingelheim Int Cyclic pyrimidin-4-carboxamides, as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
US8796297B2 (en) 2009-06-30 2014-08-05 Abbvie Inc. 4-substituted-2-amino-pyrimidine derivatives
KR101509809B1 (ko) * 2009-12-01 2015-04-08 현대자동차주식회사 차량의 커튼에어백용 램프브라켓
WO2011073154A1 (en) * 2009-12-17 2011-06-23 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists and uses thereof
WO2011115813A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories Lactam acetamides as calcium channel blockers
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
CA2801182A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
CN102796100B (zh) * 2011-05-27 2015-05-06 中国医学科学院医药生物技术研究所 一种取代苯基-(二氮杂螺环-n)-甲酮类衍生物
EP2641903B1 (de) 2012-03-19 2014-10-22 Symrise AG Dihydrobenzofuran-Derivate als Riech- und/oder Aromastoffe
TWI633087B (zh) * 2012-06-13 2018-08-21 赫孚孟拉羅股份公司 新穎二氮雜螺環烷及氮雜螺環烷
EP3590940B1 (en) 2012-09-25 2021-06-09 F. Hoffmann-La Roche AG Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
CN102942570A (zh) * 2012-12-05 2013-02-27 武汉药明康德新药开发有限公司 1-三氟甲基-2,8-二氮杂-螺[4.5]癸烷衍生物及其制备方法
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
NO3074400T3 (es) 2013-11-26 2018-04-14
EP3122751B1 (en) 2014-03-26 2019-10-30 F.Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
MA39792B1 (fr) 2014-03-26 2019-12-31 Hoffmann La Roche Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
EA201790185A1 (ru) 2014-07-15 2017-07-31 Грюненталь Гмбх Замещенные азаспиро(4.5)декановые производные
JP6601707B2 (ja) * 2015-02-15 2019-11-06 国立大学法人金沢大学 線維化判定方法
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
WO2017004537A1 (en) 2015-07-02 2017-01-05 Centrexion Therapeutics Corporation (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
MX387736B (es) 2015-09-04 2025-03-18 Hoffmann La Roche Derivados de fenoximetilo.
MX2017015034A (es) 2015-09-24 2018-04-13 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
KR20180054634A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 신규한 이환형 화합물
PE20180451A1 (es) 2015-09-24 2018-03-05 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de atx
CN107635995B (zh) 2015-09-24 2022-08-19 豪夫迈·罗氏有限公司 作为atx抑制剂的二环化合物
CN106908559B (zh) * 2015-12-23 2020-08-11 重庆华邦胜凯制药有限公司 卡泊三醇中间体l及相关杂质的分离与测定方法
MA46743A (fr) * 2016-11-08 2019-09-18 Bristol Myers Squibb Co Acides propioniques à substitution en position 3 en tant qu'inhibiteurs d'intégrine alpha v
CN108456208B (zh) * 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
CN106928092B (zh) * 2017-02-28 2019-02-15 上海微巨实业有限公司 一种间氰甲基苯甲酸甲酯的制备方法
MA49879A (fr) 2017-03-16 2020-06-24 Hoffmann La Roche Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
WO2019084075A1 (en) * 2017-10-24 2019-05-02 The Trustees Of The University Of Pennsylvania DOPAMINE RECEPTOR SELECTIVE ANTAGONISTS AND METHODS OF USING THE SAME
CA3129516A1 (en) 2018-02-28 2019-09-06 The Trustees Of The University Of Pennsylvania Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
WO2020048829A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 3,9-diazaspiro[5.5]undecane compounds
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
CN110963955A (zh) * 2018-09-30 2020-04-07 南京富润凯德生物医药有限公司 一种单氟代螺环化合物的合成方法及其中间体
CN111087336A (zh) * 2018-10-24 2020-05-01 南京富润凯德生物医药有限公司 一种双氟代螺环化合物的合成方法及其中间体
US12478621B2 (en) 2019-11-28 2025-11-25 Deutsches Krebsforschungszentrum Substituted aminoquinolones as dgkalpha inhibitors for immune activation
WO2021105116A1 (en) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
CN115989223B (zh) 2020-07-03 2024-09-20 南京艾美斐生物医药科技有限公司 使用CCR8抑制剂靶向Tregs的方法和组合物
WO2022165513A1 (en) 2021-01-29 2022-08-04 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
KR20220144510A (ko) * 2021-04-20 2022-10-27 에스케이이노베이션 주식회사 신규한 디아자스피로 화합물 및 이의 용도
CA3225439A1 (en) 2021-06-26 2022-12-29 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
CN113717180A (zh) * 2021-10-15 2021-11-30 安徽大学 一种2-Boc-2,7-二氮杂-螺[4,4]壬烷的合成方法
AR131211A1 (es) 2022-11-30 2025-02-26 Idorsia Pharmaceuticals Ltd Derivados de aril- y heteroaril-sulfonamida como moduladores de ccr8
CN116514811A (zh) * 2023-02-20 2023-08-01 药璞(上海)医药科技有限公司 一种2，7-二氮杂-螺[3，5]壬烷-2-甲酸叔丁酯的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302811D0 (sv) * 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
EP1683797A1 (en) * 2003-11-13 2006-07-26 Ono Pharmaceutical Co., Ltd. Heterocyclic spiro compound
US20070254903A1 (en) * 2003-12-23 2007-11-01 Arena Pharmaceuticals, Inc. Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof
GB2415657A (en) * 2004-06-18 2006-01-04 Kenwood Marks Ltd Cutting device for pasta making attachment to a multi-purpose kitchen machine
GB0601402D0 (en) * 2006-01-24 2006-03-08 Syngenta Participations Ag Chemical Compounds

Also Published As

Publication number Publication date
CN101305005A (zh) 2008-11-12
ZA200801511B (en) 2008-11-26
WO2007030061A1 (en) 2007-03-15
UY29781A1 (es) 2007-04-30
KR20080043396A (ko) 2008-05-16
TW200800999A (en) 2008-01-01
JP2009507070A (ja) 2009-02-19
NO20081729L (no) 2008-05-16
US20090156575A1 (en) 2009-06-18
EP1926730A4 (en) 2011-02-16
IL189528A0 (en) 2008-08-07
AU2006287976A1 (en) 2007-03-15
RU2008110915A (ru) 2009-10-20
AR055630A1 (es) 2007-08-29
CA2621187A1 (en) 2007-03-15
EP1926730A1 (en) 2008-06-04
BRPI0615634A2 (pt) 2011-05-24

Similar Documents

Publication Publication Date Title
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
ECSP109934A (es) Compuesto - 946
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
SE0301700D0 (sv) Novel compounds
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
CR9667A (es) Derivados de benzamida y usos relacionados con los mismos
CL2008003096A1 (es) Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras.
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
UY30759A1 (es) Compuestos quimicos
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
CR8778A (es) Revestimientos de azucar y metodos para estos
UY28348A1 (es) Compuestos novedosos
CY1111454T1 (el) Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
ECSP088246A (es) Nuevos derivados de benzotiazolona
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
CU20090058A7 (es) Compuestos de pirazolina y su uso y composiciones farmacéuticas
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
UY29079A1 (es) Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones
UY29607A1 (es) Compuestos quimicos
CL2011003144A1 (es) Forma cristalina e3 de bisulfato de atazanavir; composicion farmaceutica que la comprende; util para el tratamiento de enfermedades originadas por retrovirus (divisional de la solicitud 1057-05).
ECSP099425A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2
UY29648A1 (es) Derivados de piridopirimidina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones